The collaboration with Advance Trading, which is a distributor of PAS in the country, will enable Rafarma to increase production capacity of PAS and establish itself as one of leading suppliers of this product to the Russian market.
Commenting on the agreement, Rafarma Pharmaceuticals CEO Dave Anderson said, "This new contract is yet another expansion of Rafarma’s production capability, opening the door for more revenue."
During the year 2011, the PAS market in Russian Federation stood at $8.2bn, out of which nearly 20% was supplied by Advance Trading in the market, as per data provided by DSM Group.
Recently, the company has rolled out a new 270,000ft2 state-of-the-art manufacturing and distribution facility in Russia, where the company produces generic antibiotics and specialty pharmaceuticals, among others.